Table 4.
Number (%) of Adverse Events Reported by More Than 1 Participant a
| AEs, n (%) | EE/LNG Alone(n = 26) | Atogepant Alone(n = 26) | EE/LNG + Atogepant(n = 23) | Total(N = 26) |
|---|---|---|---|---|
| Headache | 4 (15.4) | 1 (3.8) | 2 (8.7) | 6 (23.1) |
| Somnolence | 1 (3.8) | 1 (3.8) | 2 (8.7) | 3 (11.5) |
| Constipation | 1 (3.8) | 3 (11.5) | 0 | 4 (14.5) |
| Diarrhea | 0 | 3 (11.5) | 0 | 3 (11.5) |
| Nausea | 1 (3.8) | 0 | 1 (4.3) | 2 (7.7) |
| Injury, poisoning, procedural complications | 1 (3.8) | 1 (3.8) | 0 | 2 (7.7) |
| Back pain | 0 | 2 (7.7) | 1 (4.3) | 3 (11.5) |
| Upper respiratory tract infection | 1 (3.8) | 0 | 1 (4.3) | 2 (7.7) |
AE indicates adverse event; EE, ethinyl estradiol; LNG, levonorgestrel.
a
Multiple instances of an AE in the same participant in a dosing category were counted as 1 instance. Participants with only 1 AE in >1 dosing category were counted once in the overall tally for that AE.